Q3 EPS Estimates for Cresco Labs Raised by Analyst

Cresco Labs Inc. (OTCMKTS:CRLBF) – Analysts at Alliance Global Partners increased their Q3 2025 earnings per share (EPS) estimates for Cresco Labs in a research note issued on Wednesday, March 12th. Alliance Global Partners analyst A. Grey now forecasts that the company will earn ($0.02) per share for the quarter, up from their prior estimate of ($0.03). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Cresco Labs’ Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.09) EPS and FY2026 earnings at ($0.08) EPS.

Separately, Atb Cap Markets cut shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.00.

Cresco Labs Price Performance

Shares of CRLBF stock opened at $0.75 on Monday. The firm has a market capitalization of $364.25 million, a price-to-earnings ratio of -3.73 and a beta of 1.79. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The stock’s 50-day simple moving average is $0.89 and its 200-day simple moving average is $1.20. Cresco Labs has a fifty-two week low of $0.70 and a fifty-two week high of $2.60.

Cresco Labs (OTCMKTS:CRLBF) last announced its earnings results on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%. The firm had revenue of $176.00 million for the quarter, compared to the consensus estimate of $172.10 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.